Bharat Biotech’s COVAXIN Phase 3 results show interim clinical efficacy of 81%
Data from 25,800 participants that received the COVAXIN vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well-tolerated. It demonstrated 81% interim efficacy in preventing COVID-19 after the second dose